Replimune Group Inc [REPL] stock is trading at $5.53, down -2.64%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The REPL shares have gain 5.33% over the last week, with a monthly amount glided 47.47%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Replimune Group Inc [NASDAQ: REPL] stock has seen the most recent analyst activity on July 30, 2025, when Cantor Fitzgerald upgraded its rating to a Overweight. Previously, H.C. Wainwright downgraded its rating to Neutral on July 23, 2025. On July 23, 2025, downgrade downgraded it’s rating to Underperform but maintained its price target of $2 on the stock. Barclays downgraded its rating to a Equal Weight but stick to its price target of $3 on July 23, 2025. Wedbush downgraded its rating to a Neutral but $4 remained the price target by the analyst firm on July 22, 2025. Piper Sandler downgraded its rating to Neutral for this stock on July 22, 2025, but kept the price target unchanged to $3. In a note dated July 22, 2025, Leerink Partners downgraded an Market Perform rating on this stock but restated the target price of $3.
Replimune Group Inc [REPL] stock has fluctuated between $2.68 and $17.00 over the past year. Currently, Wall Street analysts expect the stock to reach $25.5 within the next 12 months. Replimune Group Inc [NASDAQ: REPL] shares were valued at $5.53 at the most recent close of the market. An investor can expect a potential return of 361.12% based on the average REPL price forecast.
Analyzing the REPL fundamentals
Gross Profit Margin for this corporation currently stands at -1.92% with Operating Profit Margin at -200.19%, Pretax Profit Margin comes in at -190.05%, and Net Profit Margin reading is -190.37%. To continue investigating profitability, this company’s Return on Assets is posted at -0.6, Equity is -0.69 and Total Capital is -0.72. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.23.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.41 points at the first support level, and at 5.28 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.69, and for the 2nd resistance point, it is at 5.84.
Ratios To Look Out For
For context, Replimune Group Inc’s Current Ratio is 6.94. In addition, the Quick Ratio stands at 6.94 and the Cash Ratio stands at 1.63.
Transactions by insiders
Recent insider trading involved Hill Emily Luisa, Chief Financial Officer, that happened on Aug 15 ’25 when 9154.0 shares were sold. Director, Astley-Sparke Philip completed a deal on May 20 ’25 to sell 32279.0 shares. Meanwhile, Chief Medical Officer Xynos Konstantinos sold 7952.0 shares on May 20 ’25.
